Crinetics Pharmaceuticals (CRNX) reported a Q4 net loss late Thursday of $0.88 per diluted share, narrowing from the loss of $0.90 a year earlier.
Analysts polled by FactSet expected a loss of $0.89.
No revenue was reported for the quarters that ended Dec. 31 in 2023 and 2024. Analysts surveyed by FactSet projected $700,000 in Q4 2024.
As of Dec. 31, the company had $1.4 billion in cash, cash equivalents and investments, enough to fund the current operating plan into 2029.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。